TNFRSF10A and colorectal cancer: When the expression of TRAIL-receptors was considered in relation to the survival of colorectal cancer patients, TRAIL-R1 staining intensity (high expression vs. low/no expression) was associated with a significantly better prognosis: the 5-year survival of patients bearing tumors with overall higher TRAIL-R1 expression was 70% vs. 56% of patients with low or altogether no staining for TRAIL-R1; the 10-year survival for these patients was respectively 31% vs. 25% (p = 0.008; Figure 4A).